What is it and what does it include?
The GERAS II study was a prospective, multicenter, observational study that aimed to assess societal costs and resource use associated with AD among patients and their primary caregivers in Italy and Spain. Eligible patients were males and females aged ≥55 years old, who had received a diagnosis of probable AD according to the National Institute on Aging and Alzheimer’s Association and with a Mini-Mental State Examination (MMSE) score of 26 or less. The costs associated with the resources used were calculated. Costs were broken down into patient healthcare costs, patient social care costs and caregiver informal care costs.
How can I use this dataset to advance my research?
This dataset is ideal if:
- you’re analyzing care costs and their association to AD severity over time.
- you’re studying health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in Italy and Spain.
Has this dataset helped researchers understand Alzheimer’s and other dementias better?
Of course!
- Resource utilization, Clinical Costs, AD, Spain:
In 2017, in a study of a total of 380 patients, researchers showed that the total monthly societal costs for AD increased with increasing AD dementia severity in Spain, with costs almost doubling for patients with MS/S AD dementia compared with those with mild AD dementia. July 2017 – DOI: https://doi.org/10.1017/S1041610217001211